Treatment delivered in the phase III pivotal trial

ABRAXANE treatment duration for non-small cell lung cancer

ABRAXANE + carboplatin arm

Range: 1-31 cycles1

  • Patients in the study were treated until disease progression or development of unacceptable toxicity
Dose modifications seen in the clinical trial

Treatment delivered in the phase III pivotal trial

ABRAXANE treatment duration for non-small cell lung cancer

ABRAXANE + carboplatin arm

Range: 1-31 cycles1

Dose modifications seen in the clinical trial
  • Patients in the study were treated until disease progression or development of unacceptable toxicity

INDICATION

ABRAXANE is indicated for the first-line treatment of locally advanced or metastatic non–small cell lung cancer, in combination with carboplatin, in patients who are not candidates for curative surgery or radiation therapy.

INDICATION

ABRAXANE is indicated for the first-line treatment of locally advanced or metastatic non–small cell lung cancer, in combination with carboplatin, in patients who are not candidates for curative surgery or radiation therapy.